Zobrazeno 1 - 10
of 140
pro vyhledávání: ''
Publikováno v:
Cerebrovascular Diseases. 50:162-170
Background: While endovascular stroke treatment (EST) of large vessel occlusions in acute ischemic stroke (AIS) is proven to be safe and effective, there are subgroups of patients with increased rates of hemorrhages. Our goal was to identify risk fac
Autor:
Richard J. Barohn, Mazen M. Dimachkie, Mohammed H. Alanazy, Nadeem Shafique Butt, Ahmad R. Abuzinadah
Publikováno v:
Eur Neurol
Objective: The aim of the study was to estimate the exacerbation incidence rate (IR) in acetylcholine receptor antibody (AChR)-positive generalized myasthenia gravis (MG) and its predictors. Methods: The primary outcome in this retrospective study wa
Autor:
Alan T. Davis, Laurel M. Packard, Yao Cheng, Jiangyong Min, Fnu Rameez, Justin Singer, Muhib Khan, Nabil Wees, Philip McCarthy, Nadeem Khan
Publikováno v:
Cerebrovascular Diseases Extra
Cerebrovascular Diseases Extra, Vol 10, Iss 3, Pp 159-165 (2020)
Cerebrovascular Diseases Extra, Vol 10, Iss 3, Pp 159-165 (2020)
Objective: Our study aims to evaluate the impact of a stay-at-home order on stroke metrics during the 2019-novel coronavirus (COVID-19) pandemic. Methods: Data on baseline characteristics, stroke subtype, initial National Institutes of Health Stroke
Autor:
René Hurlemann, Oliver Kaut, Tamara Schaprian, Thomas Klockgether, Marcus Grobe-Einsler, Ina R. Vogt
Publikováno v:
Neurodegenerative diseases 20(2-3), 104-109 (2020). doi:10.1159/000510057
Background: Rivastigmine is an acetylcholine esterase inhibitor which is commonly used as therapy for dementia in Alzheimer’s disease and Parkinson’s disease (PD). Recently, a randomized controlled trial demonstrated a positive effect of rivastig
Autor:
Masakatsu Nishikawa, Akira Ogawa, Shinsuke Nanto, Kazunori Toyoda, Yasuo Ikeda, Takanari Kitazono, Kenji Abe, Kazuo Kitagawa
Publikováno v:
Cerebrovasc Dis
Introduction: The safety of prasugrel in elderly and/or low body weight Japanese patients with ischemic stroke who have a relatively high bleeding risk with antiplatelet therapy remains unknown. Objective: We aimed to investigate the safety and effic
Autor:
Liyuan Zhou, Qixiong Qin, Haihong Li, Ya Chen, Yunfei Wei, Xuemei Quan, Jing Wei, Zhijian Liang, Shengyu Li, Qingqing Yang, Guohui Li, Dacheng Wang
Publikováno v:
European Neurology. 83:41-48
Background: The occurrence of ischemic stroke in patients with non-Hodgkin lymphoma (NHL) is not well understood. This study aimed to determine independent risk factors to identity ischemic stroke in non-Hodgkin lymphoma-associated ischemic stroke (N
Publikováno v:
Neuroepidemiology. 54:58-63
Introduction: Multiple system atrophy (MSA) is a rare rapidly progressive atypical Parkinson disorder presenting clinically with parkinsonism and/or a cerebellar syndrome in combination with dysautonomia. Severe neuroinflammation develops along with
Autor:
Won Tae Yoon, Jin Whan Cho, Ji Hyun Choi, Jae Woo Kim, Beomseok Jeon, Oh Dae Kwon, Jee Young Lee, Seong Beom Koh, Hyeo Il Ma, Ho-Won Lee, Jong Min Kim, Hee Tae Kim, Jong Sam Baik
Publikováno v:
Neurodegenerative Diseases. 19:171-177
Introduction: Impulse control disorder (ICD) in Parkinson’s disease (PD) is a critical nonmotor symptom with personality or neuropsychiatric traits contributing to ICD. Objective: This study aimed to identify predictive traits for persistent or par
Publikováno v:
Neuroepidemiology. 52:220-226
Background: The prevalence of drug-induced parkinsonism (DIP) has been reported with the use of trimetazidine (TMZ), an antianginal medication available in Asian and European countries. Very few studies have evaluated the association between DIP and
Autor:
Makiko Takeichi, Jyoji Nakagawara, Susumu Miyamoto, Shoichiro Sato, Yoko Kidani, Toshiyuki Sunaya, Takanori Ikeda, Satoshi Yamanaka, Satoshi Ogawa, Yutaka Okayama, Kazuo Minematsu, Takanari Kitazono, Yuji Murakawa
Publikováno v:
Cerebrovascular Diseases. 48:53-60
Introduction: Prior stroke is a risk factor for stroke and bleeding during anticoagulation in patients with atrial fibrillation (AF). Although rivaroxaban is widely prescribed to reduce their risk of stroke in patients with nonvalvular AF (NVAF), the